Identity
- Security key
- 17056
- Ticker
- IMUX
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2014-04-17
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- IMUX
Detail
Enriched 2026-08-14 20:47
- Market cap
- $217,356,359.31
- Shares outstanding (class)
- 13,621,483
- Shares outstanding (weighted)
- 13,644,467
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 95
- Location
- NEW YORK, X1
- Homepage
- https://www.imux.com
- Description
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Market cap and share counts drift.